In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
The in-vitro activity of moxifloxacin, a new fluoroquinolone, against Chlamydia species was investigated. The minimal inhibitory concentration of moxifloxacin for 10 standard strains of different Chlamydia species and 15 wild-type strains of Chlamydia pneumoniae isolated in Japan, which were morphologically different from clinical isolates from the United States, ranged from 0.031 to 0.125 microg/ml. The activity of moxifloxacin was almost the same as those of sparfloxacin, and it was 16, 8, 2, and 2 times more active than ciprofloxacin, levofloxacin, grepafloxacin, and tosufloxacin, respectively. The minimal chlamydiacidal concentration of moxifloxacin ranged from 0.031 to 0.125 microg/ml. These results suggest that moxifloxacin has potential effects against Chlamydia species.
Miyashita
Naoyuki
N
Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan. nao@med.kawasaki-m.ac.jp
Fukano
Hiroshi
H
Yoshida
Koichiro
K
Niki
Yoshihito
Y
Matsushima
Toshiharu
T
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D002689:Chlamydia / Q000187:drug effects*; D017714:Community-Acquired Infections / Q000188:drug therapy; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D011804:Quinolines
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin